Global Structural Heart Disease Intervention Devices Market Growth 2023-2029

Global Structural Heart Disease Intervention Devices Market Growth 2023-2029

The global Structural Heart Disease Intervention Devices market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Structural Heart Disease Intervention Devices is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Structural Heart Disease Intervention Devices is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Structural Heart Disease Intervention Devices is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Structural Heart Disease Intervention Devices players cover Abbott Structural Heart, Philips, Japen Lifeline, Neovasc, Append Medical, Transverse Medical, Cardiomech, Thubrikar Aortic Valve Inc and Boston Scientific, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Structural heart disease intervention devices are medical devices used to treat heart diseases by repairing or replacing diseased or defective heart tissues or structures through minimally invasive procedures. Common types of structural heart disease intervention devices include:


Atrial septal defect closure devices: used to treat congenital heart defects by inserting a device into the heart through a catheter and placing a closure device over the defect to prevent blood from flowing from the left atrium to the right atrium.


Mitral valve repair devices: used to treat mitral valve regurgitation or prolapse by inserting a device into the heart through a catheter and placing a repair device over the damaged or prolapsed valve.


Transcatheter aortic valve replacement devices: used to treat aortic valve stenosis or regurgitation by inserting an artificial valve into the heart through a catheter and replacing the damaged aortic valve.


Cerebral aneurysm coiling devices: used to treat cerebral aneurysms or narrowing of the blood vessels in the brain by inserting a coil into the blood vessel through a catheter to strengthen the blood vessel and prevent blood from leaking out.


These structural heart disease intervention devices have been widely used in clinical practice and have achieved good treatment results, significantly improving the cardiovascular function of patients and enhancing their quality of life.

LPI (LP Information)' newest research report, the “Structural Heart Disease Intervention Devices Industry Forecast” looks at past sales and reviews total world Structural Heart Disease Intervention Devices sales in 2022, providing a comprehensive analysis by region and market sector of projected Structural Heart Disease Intervention Devices sales for 2023 through 2029. With Structural Heart Disease Intervention Devices sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Structural Heart Disease Intervention Devices industry.

This Insight Report provides a comprehensive analysis of the global Structural Heart Disease Intervention Devices landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Structural Heart Disease Intervention Devices portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Structural Heart Disease Intervention Devices market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Structural Heart Disease Intervention Devices and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Structural Heart Disease Intervention Devices.

This report presents a comprehensive overview, market shares, and growth opportunities of Structural Heart Disease Intervention Devices market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Atrial Interventional Class
Cardiovascular Intervention

Segmentation by application
Congenital Heart Disease Treatment
Valvular Heart Disease Treatment
Cardiomyopathy Treatment
Aneurysm and Arterial Valve Disease Treatment
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Structural Heart
Philips
Japen Lifeline
Neovasc
Append Medical
Transverse Medical
Cardiomech
Thubrikar Aortic Valve Inc
Boston Scientific
Edwards Lifesciences Corporation
Biomerics
LivaNova PLC

Key Questions Addressed in this Report

What is the 10-year outlook for the global Structural Heart Disease Intervention Devices market?

What factors are driving Structural Heart Disease Intervention Devices market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Structural Heart Disease Intervention Devices market opportunities vary by end market size?

How does Structural Heart Disease Intervention Devices break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.